Form 8-K - Current report:
SEC Accession No. 0001821586-24-000007
Filing Date
2024-02-29
Accepted
2024-02-29 08:03:47
Documents
15
Period of Report
2024-02-29
Items
Item 2.02: Results of Operations and Financial Condition

Document Format Files

Seq Description Document Type Size
1 8-K mnlk-20240229.htm   iXBRL 8-K 27544
2 EX-99.1 moonlake-pressreleasexq420.htm EX-99.1 139265
  Complete submission text file 0001821586-24-000007.txt   308874

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mnlk-20240229.xsd EX-101.SCH 1898
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mnlk-20240229_lab.xml EX-101.LAB 24055
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mnlk-20240229_pre.xml EX-101.PRE 12482
16 EXTRACTED XBRL INSTANCE DOCUMENT mnlk-20240229_htm.xml XML 2816
Mailing Address DORFSTRASSE 29 ZUG V8 6300
Business Address DORFSTRASSE 29 ZUG V8 6300 41 41 510 8022
MoonLake Immunotherapeutics (Filer) CIK: 0001821586 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39630 | Film No.: 24698971
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)